Jul 24, 2007 by Brian LawlerSchering Doesn't SlowSchering continues its strong sales and earnings growth.
Jul 23, 2007 by Brian LawlerAcquisitive Ways Paying Off for GenzymeA recently acquired drug yields positive study results.
Jul 23, 2007 by Brian LawlerGilead's Great GrowthThe drugmaker announces another great quarter of growth.
Jul 23, 2007 by Brian LawlerMedarex Cheering for Its PartnerMedarex's partner advances one of its compounds into later stage clinical testing.
Jul 23, 2007 by Brian LawlerGPC's Date With the FDAA document released by the FDA outlines its concerns with GPC's lead drug.
Jul 23, 2007 by Brian LawlerA Setback for Elan and BiogenElan and Biogen receive negative news about Tysabri.
Jul 20, 2007 by Brian LawlerInterMune's Sharp FocusThe Fool interviews the CEO of a biotech with a specialized approach.
Jul 20, 2007 by Brian LawlerGlaxo Heats Up the Vaccine BattleGlaxoSmithKline's cervical cancer vaccine gets a positive recommendation.
Jul 19, 2007 by Brian LawlerWill Encysive's FDA Challenge Fail?Encysive gets set for a showdown with the FDA.
Jul 18, 2007 by Brian LawlerPDL Shareholder Battle: Round 3Third Point continues to press its point about management's weakness.
Jul 17, 2007 by Brian LawlerStill Strong at NovartisIts latest results might be a surprise because of the challenges the company has faced this year.
Jul 16, 2007 by Brian LawlerIdenix Gets StoppedThe FDA puts a hold on the company's lead drug candidate.
Jul 12, 2007 by Brian LawlerIs It Time to Buy Genentech Yet?Genentech announces positive second-quarter results, but investors remain worried.
